• Collaboration aims to develop nanobodies against cancer
    ENPICOM’s immune repertoire data analysis software solution.


Collaboration aims to develop nanobodies against cancer

Mar 18 2024

ENPICOM, a leading provider of bioinformatics software solutions, announces a strategic partnership with Erasmus Medical Center (MC), a renowned institution in cancer research. The collaboration aims to advance the identification and development of nanobodies against cancer utilising ENPICOM’s immune repertoire data analysis services and software solutions.

Dr Guido Jenster, project lead and Professor of Experimental Urological Oncology at Erasmus MC, expressed confidence in the collaboration: "We selected ENPICOM to support our project because of their unique software tailored for antibody discovery workflows and their ability to integrate seamlessly with our team. By leveraging our collective expertise, we aim to make significant strides in discovering novel cancer therapeutics." The partnership is supported by funding from the Ministry of Economic Affairs through the PPP Allowance provided by the Top Sector Life Sciences & Health to promote public-private collaborations.

Paul van der Velde, CEO of ENPICOM, shares his enthusiasm: "We are thrilled to collaborate with Erasmus MC, a leader in cancer research, to explore the potential of nanobody-based treatments. Nanobodies offer promising advantages in cancer therapy due to their small size, enhanced tissue penetration, and greater stability."

Compared to traditional antibodies, nanobodies boast a smaller size, facilitating better tissue penetration and tumour infiltration. Their longer CDR3 regions enable superior recognition of hidden epitopes, while their single-chain structure enhances stability and ease of production and engineering.

ENPICOM’s IGX Platform specialises in analysing antibody sequencing data to identify a diverse range of developable candidates. The platform seamlessly integrates sequence and experimental assay data, facilitating efficient cluster, phylogenetic, and display enrichment analyses in a secure and scalable environment. Additionally, the platform enables high-throughput structural modelling of antibodies to pinpoint the most promising candidates for further development.

In addition to the IGX Platform, ENPICOM offers comprehensive immune repertoire sequencing and analysis services in collaboration with Cerba Research. Furthermore, ENPICOM provides on-demand repertoire analysis and custom development to support non-standard R&D initiatives, combining immunology, bioinformatics, and software engineering expertise to tackle challenges related to adaptive immune repertoires.

More information online

Digital Edition

Lab Asia 31.2 April 2024

April 2024

In This Edition Chromatography Articles - Approaches to troubleshooting an SPE method for the analysis of oligonucleotides (pt i) - High-precision liquid flow processes demand full fluidic c...

View all digital editions


Expomed Eurasia

Apr 25 2024 Istanbul, Turkey

AOCS Annual Meeting & Expo

Apr 28 2024 Montreal, Quebec, Canada

SETAC Europe

May 05 2024 Seville, Spain

InformEx Zone at CPhl North America

May 07 2024 Pennsylvania, PA, USA

ISHM 2024

May 14 2024 Oklahoma City, OK, USA

View all events